Patents by Inventor Tomoko Oda

Tomoko Oda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutic agent for meibomian dysfunction
    Patent number: 11951098
    Abstract: A method for suppressing obstruction of meibomian gland in a mammalian subject, the method comprising administering to the mammalian subject an eye drop comprising 0.01 to 0.5% (w/v) of sirolimus or a pharmaceutically acceptable salt thereof as a sole active ingredient, wherein the eye drop is administered to an eye of the mammalian subject 1 to 2 times per day.
    Type: Grant
    Filed: February 16, 2023
    Date of Patent: April 9, 2024
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Hideki Miyake, Tomoko Oda, Daisuke Shii
  • SULFUR-CONTAINING COMPOUND USEFUL FOR TREATING OR PREVENTING PRESBYOPIA
    Publication number: 20230346744
    Abstract: The present disclosure provides an agent for treating or preventing an eye disease such as presbyopia, comprising, as an active ingredient, a sulfur-containing compound having a specified structure.
    Type: Application
    Filed: May 25, 2021
    Publication date: November 2, 2023
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Masatomo KATO, Tomoko ODA, Takahiro HONDA
  • THERAPEUTIC AGENT FOR MEIBOMIAN DYSFUNCTION
    Publication number: 20230190716
    Abstract: A method for suppressing obstruction of meibomian gland in a mammalian subject, the method comprising administering to the mammalian subject an eye drop comprising 0.01 to 0.5% (w/v) of sirolimus or a pharmaceutically acceptable salt thereof as a sole active ingredient, wherein the eye drop is administered to an eye of the mammalian subject 1 to 2 times per day.
    Type: Application
    Filed: February 16, 2023
    Publication date: June 22, 2023
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Hideki Miyake, Tomoko ODA, Daisuke SHII
  • Therapeutic agent for meibomian dysfunction
    Patent number: 11612590
    Abstract: A method for suppressing obstruction of meibomian gland in a mammalian subject, the method comprising administering to the mammalian subject an eye drop comprising 0.01 to 0.5% (w/v) of sirolimus or a pharmaceutically acceptable salt thereof as a sole active ingredient, wherein the eye drop is administered to an eye of the mammalian subject 1 to 2 times per day.
    Type: Grant
    Filed: May 7, 2019
    Date of Patent: March 28, 2023
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Hideki Miyake, Tomoko Oda, Daisuke Shii
  • URSODEOXYCHOLIC ACID-CONTAINING AGENT FOR TREATING OR PREVENTING PRESBYOPIA
    Publication number: 20230040386
    Abstract: The present disclosure provides an agent for treating or preventing eye diseases such as presbyopia, comprising, as an active ingredient, ursodeoxycholic acid or an amide conjugate of ursodeoxycholic acid, or an ester thereof, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 2, 2022
    Publication date: February 9, 2023
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Masatomo KATO, Tomoko ODA, Kazutaka KIDO
  • Ursodeoxycholic acid-containing agent for treating or preventing presbyopia
    Patent number: 11419880
    Abstract: The present disclosure provides an agent for treating or preventing eye diseases such as presbyopia, comprising, as an active ingredient, ursodeoxycholic acid or an amide conjugate of ursodeoxycholic acid, or an ester thereof, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 9, 2021
    Date of Patent: August 23, 2022
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Masatomo Kato, Tomoko Oda, Kazutaka Kido
  • LIPOIC ACID PRODRUG
    Publication number: 20220151989
    Abstract: The present disclosure provides and an agent for treating or preventing an eye disease such as presbyopia, comprising, as an active ingredient, a lipoic acid prodrug having a specified structure.
    Type: Application
    Filed: April 16, 2020
    Publication date: May 19, 2022
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Masatomo KATO, Tomoko ODA, Shinji TAKAOKA, Takahiro HONDA, Tatsuya HATA
  • URSODEOXYCHOLIC ACID-CONTAINING AGENT FOR TREATING OR PREVENTING PRESBYOPIA
    Publication number: 20220096497
    Abstract: The present disclosure provides an agent for treating or preventing eye diseases such as presbyopia, comprising, as an active ingredient, ursodeoxycholic acid or an amide conjugate of ursodeoxycholic acid, or an ester thereof, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: December 9, 2021
    Publication date: March 31, 2022
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Masatomo KATO, Tomoko ODA, Kazutaka KIDO
  • URSODEOXYCHOLIC ACID-CONTAINING AGENT FOR TREATING OR PREVENTING PRESBYOPIA
    Publication number: 20220072012
    Abstract: The present disclosure provides an agent for treating or preventing eye diseases such as presbyopia, comprising, as an active ingredient, ursodeoxycholic acid or an amide conjugate of ursodeoxycholic acid, or an ester thereof, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: December 17, 2019
    Publication date: March 10, 2022
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Masatomo KATO, Tomoko ODA, Kazutaka KIDO
  • AGENT CONTAINING 4-PHENYLBUTYRATE, FOR PREVENTING OR TREATING PRESBYOPIA
    Publication number: 20220062209
    Abstract: The present disclosure provides an agent for treating or preventing eye diseases such as presbyopia, comprising, as an active ingredient, 4-phenylbutyric acid or an ester thereof, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: December 17, 2019
    Publication date: March 3, 2022
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Masatomo KATO, Tomoko ODA, Kensuke NOZAKI
  • METHOD FOR CHANGING CONDITION OF EYELID OF HAIRLESS ANIMAL
    Publication number: 20210011004
    Abstract: A method for changing a condition of an eyelid of a hairless animal, a model animal for evaluating a therapeutic or prophylactic effect against an eyelid disease obtained by the method, a method for producing the model animal, a method of screening using the model animal and a substance having a therapeutic or prophylactic effect against an eyelid disease selected by the method of screening, and a therapeutic or prophylactic agent against an eyelid disease containing the substance as an active ingredient.
    Type: Application
    Filed: September 28, 2020
    Publication date: January 14, 2021
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Hideki MIYAKE, Tomoko ODA
  • [4-(1,3,3-TRIMETHYL-2-OXO-3,4-DIHYDRO-1H-QUINOXALIN-7-YL)PHENOXY]ETHYLOXY COMPOUND OR SALT THEREOF
    Publication number: 20190359577
    Abstract: The present invention relates to defined quinoxalin-2-one compounds or a pharmaceutically acceptable salt or a hydrate or a solvate thereof. The compounds, salts or hydrates have a glucocorticoid receptor agonist activity, and are useful as a medicine, in particular as a prophylactic or therapeutic agent for a glucocorticoid receptor related disease.
    Type: Application
    Filed: August 6, 2019
    Publication date: November 28, 2019
    Applicant: Santen Pharmaceutical Co., Ltd.
    Inventors: Kenji KAWASHIMA, Yusuke YAMAZAKI, Shinji TAKAOKA, Daisuke SHII, Tomoko ODA, Takahiro MATSUYAMA
  • [4-(1,3,3-trimethyl-2-OXO-3,4-dihydro-1H-quinoxalin-7-yl)phenoxy]ethyloxy compound or salt thereof
    Patent number: 10435379
    Abstract: The present invention relates to defined quinoxalin-2-one compounds or a pharmaceutically acceptable salt or a hydrate or a solvate thereof. The compounds, salts or hydrates have a glucocorticoid receptor agonist activity, and are useful as a medicine, in particular as a prophylactic or therapeutic agent for a glucocorticoid receptor related disease.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: October 8, 2019
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Kenji Kawashima, Yusuke Yamazaki, Shinji Takaoka, Daisuke Shii, Tomoko Oda, Takahiro Matsuyama
  • THERAPEUTIC AGENT FOR MEIBOMIAN DYSFUNCTION
    Publication number: 20190255026
    Abstract: A method for suppressing obstruction of meibomian gland in a mammalian subject, the method comprising administering to the mammalian subject an eye drop comprising 0.01 to 0.5% (w/v) of sirolimus or a pharmaceutically acceptable salt thereof as a sole active ingredient, wherein the eye drop is administered to an eye of the mammalian subject 1 to 2 times per day.
    Type: Application
    Filed: May 7, 2019
    Publication date: August 22, 2019
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Hideki MIYAKE, Tomoko ODA, Daisuke SHII
  • [4-(1,3,3-TRIMETHYL-2-OXO-3,4-DIHYDRO-1H-QUINOXALIN-7-YL)PHENOXY]ETHYLOXY COMPOUND OR SALT THEREOF
    Publication number: 20190106393
    Abstract: The present invention relates to defined quinoxalin-2-one compounds or a pharmaceutically acceptable salt or a hydrate or a solvate thereof. The compounds, salts or hydrates have a glucocorticoid receptor agonist activity, and are useful as a medicine, in particular as a prophylactic or therapeutic agent for a glucocorticoid receptor related disease.
    Type: Application
    Filed: December 5, 2018
    Publication date: April 11, 2019
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Kenji KAWASHIMA, Yusuke YAMAZAKI, Shinji TAKAOKA, Daisuke SHII, Tomoko ODA, Takahiro MATSUYAMA
  • [4-(1,3,3-trimethyl-2-oxo-3,4-dihydro-1H-quinoxalin-7-yl)phenoxy]ethyloxy compound or salt thereof
    Patent number: 10189796
    Abstract: The present invention relates to a novel [4-(1,3,3-trimethyl-2-oxo-3,4-dihydro-1H-quinoxalin-7-yl)phenoxy]ethyloxy compound or a salt thereof. The compound or a salt thereof of the present invention has a glucocorticoid receptor agonist activity, and is useful as a medicine, in particular as a prophylactic or therapeutic agent for the glucocorticoid receptor related disease.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: January 29, 2019
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Kenji Kawashima, Yusuke Yamazaki, Shinji Takaoka, Daisuke Shii, Tomoko Oda, Takahiro Matsuyama
  • Method for changing condition of an eyelid for evaluation of an eyelid disease involving plugging of meibomian gland orifices and/or telangiectasia by administration of complete freund's adjuvant
    Patent number: 10143761
    Abstract: A method for changing a condition of an eyelid of a mammal excluding a human, a model animal for evaluating a therapeutic or prophylactic effect against an eyelid disease obtained by the method, a method for producing the model animal, a method of screening using the model animal and a substance having a therapeutic or prophylactic effect against an eyelid disease selected by the method of screening, and a therapeutic or prophylactic agent against an eyelid disease containing the substance as an active ingredient.
    Type: Grant
    Filed: June 18, 2013
    Date of Patent: December 4, 2018
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Hideki Miyake, Tomoko Oda
  • METHOD FOR CHANGING CONDITION OF EYELID OF HAIRLESS ANIMAL
    Publication number: 20180246081
    Abstract: A method for changing a condition of an eyelid of a hairless animal, a model animal for evaluating a therapeutic or prophylactic effect against an eyelid disease obtained by the method, a method for producing the model animal, a method of screening using the model animal and a substance having a therapeutic or prophylactic effect against an eyelid disease selected by the method of screening, and a therapeutic or prophylactic agent against an eyelid disease containing the substance as an active ingredient.
    Type: Application
    Filed: April 27, 2018
    Publication date: August 30, 2018
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Hideki MIYAKE, Tomoko ODA
  • [4-(1,3,3-TRIMETHYL-2-OXO-3,4-DIHYDRO-1H-QUINOXALIN-7-YL)PHENOXY]ETHYLOXY COMPOUND OR SALT THEREOF
    Publication number: 20180244633
    Abstract: The present invention relates to a novel [4-(1,3,3-trimethyl-2-oxo-3,4-dihydro-1H-quinoxalin-7-yl)phenoxy]ethyloxy compound or a salt thereof. The compound or a salt thereof of the present invention has a glucocorticoid receptor agonist activity, and is useful as a medicine, in particular as a prophylactic or therapeutic agent for the glucocorticoid receptor related disease.
    Type: Application
    Filed: August 25, 2016
    Publication date: August 30, 2018
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Kenji KAWASHIMA, Yusuke YAMAZAKI, Shinji TAKAOKA, Daisuke SHII, Tomoko ODA, Takahiro MATSUYAMA
  • THERAPEUTIC AGENT FOR MEIBOMIAN DYSFUNCTION
    Publication number: 20180021314
    Abstract: A method for treatment of meibomian gland dysfunction in a mammalian subject, the method involving administering to the mammalian subject an eye drop comprising 0.01 to 0.5% (w/v) of sirolimus or a pharmaceutically acceptable salt thereof as a sole active ingredient, wherein the eye drop is administered to the eyes of the mammalian subject 1 to 2 times per day.
    Type: Application
    Filed: October 2, 2017
    Publication date: January 25, 2018
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Hideki MIYAKE, Tomoko ODA, Daisuke SHII